TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01921894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
Study: NCT00244764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW786034
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Study: NCT00954590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon (latrepirdine)
Description: 20 mg orally three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally three times daily
Study: NCT00223925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Study: NCT01961427

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
Study: NCT01120626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: donepezil (2.5 mg to 10.0 mg per day for 12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
Study: NCT00699790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCR2 Antagonist
Description: Tablets, Oral, 50 mg, once daily, 12 weeks
Study: NCT02818257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip B
Description: Adhesive strip B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip B
Description: Adhesive strip B
Study: NCT00223925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03913065

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: Head computed tomography on patients still unconscious 48 hours after cardiac arrest.Visual evaluation of generalized oedema (eye-balling). Manual and automated measurement of the differentiation of gray and white matter (GWR) using circular regions of interest (ROI).
Study: NCT00828295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: palonosetron IV 1 mcg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: palonosetron 3mcg/kg IV
Study: NCT03902548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]P16-129
Description: Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]P16-129
Description: Injection of \< 10 mCi \[18F\]P16-129 followed by PET/CT scanning
Study: NCT01031394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequency of Aerobic/Resistance Training - 3 to 3
Description: comparing group results based upon frequency of exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequency of Aerobic/Resistance Training - 3 to 3
Description: comparing group results based upon frequency of exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frequency of Aerobic/Resistance Training - 3 to 3
Description: comparing group results based upon frequency of exercise
Study: NCT00252967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 mg of Atorvastatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04292873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Enteral supplement of 569,600 IU vitamin D
Study: NCT00905606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Tablets
Study: NCT00699790

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0mg, once daily, 12 weeks
Study: NCT02818257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip C
Description: Adhesive strip C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strip C
Description: Adhesive strip C
Study: NCT03427073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALM201
Description: Drug: ALM201 administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALM201
Description: Drug: ALM201 administered subcutaneously
Study: NCT03984409

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kroger low calorie orange juice beverage
Description: Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Kroger low calorie orange juice beverage
Description: Kroger low calorie orange juice beverage will be consumed for 7 days followed by a 24 hour urine collection with Litholink to see if urine alkalization similar to potassium citrate can be achieved
Study: NCT00858832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methergine
Description: Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
Study: NCT01787071

Intervention type: OTHER
Intervention: Fluid challenge
Description: Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
Study: NCT02966457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate Sodium
Description: Selective oral intestinal decolonization
Study: NCT03883061

Intervention type: OTHER
Intervention: regular medical treatment
Description: regular medical treatment
Study: NCT03475225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Cholecalciferol delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral
Description: manufactured to mimic Cholecalciferol
Study: NCT04048577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing Interruption of Natalizumab
Description: Planned 12 week dosing interruption of natalizumab
Study: NCT01329757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GH
Description: Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of a subcutaneously injected daily dose of placebo for 1 year
Study: NCT01564979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preseptal injection of botulinum toxin type A
Description: botulinum toxin type A (Botox)2.5 units, 5 points

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pretarsal injection of Botulinum toxin type A
Description: Botulinum toxin type A 2,5 units, 5 points
Study: NCT02235818

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotape
Description: Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Counterforce elbow brace
Description: Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
Study: NCT01504503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil Hydrochloride Tablets 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept 10 mg Tablets
Study: NCT04513145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine is a local anesthetic that is FDA approved for local anesthetic nerve block.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Injection
Description: Saline will be used as a placebo injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: All subjects participating in this study will undergo primary total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: All subjects participating in this study will undergo primary total knee arthroplasty
Study: NCT04551443

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion placebo
Description: Intravenous infusion placebo or WJMSCs in patients with AMI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion placebo
Description: Intravenous infusion placebo or WJMSCs in patients with AMI

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion WJMSCs
Description: Intravenous infusion WJMSCs or placebo in patients with AMI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous infusion WJMSCs
Description: Intravenous infusion WJMSCs or placebo in patients with AMI
Study: NCT04073615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Film-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Film-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trifluridine/Tipiracil
Description: Film-coated tablets
Study: NCT04401059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elemene plus first or third generation EGFR-TKIs
Description: Elemene Injectable Emulsion: 20ml: 88mg, 6 injections each time, once a day, continuous intravenous drip for 5 days. Continue to use Elemene Oral Emulsion. For specific usage, refer to the drug label.~Elemene Oral Emulsion: 20ml: 176mg, 1 dose each time, 3 times a day. Use the Elemene Oral Emulsions until the disease progresses, the intolerable toxicity, the patient withdraws from the study, or dies for any reason.~First or third generation EGFR-TKIs: refer to the drug label.
Study: NCT04565938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of adhesive for the restoration of dental lesions with resin composite
Description: 1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) and dentin (15sec) etching with phosphoric acid~4. Application of ExciTE (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec with 800mW/cm2 light intensity (Cure TC-01, Spring Health Products, Inc, Norristown, PA, USA)~5. Composite-resin application using a transparent cervical matrix (Kerr-Hawe, Orange, CA, USA) and curing for 40sec~6. Finishing and polishing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of adhesive for the restoration of dental lesions with resin composite
Description: 1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Application of AdheSE One (Ivoclar/Vivadent, AG, Shaan, Lichtenstein) and curing for 10sec~4. Composite-resin application using a transparent cervical matrix and curing for 40sec~5. Finishing and polishing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of adhesive for the restoration of dental lesions with resin composite
Description: 1. Mechanical removal of sclerotic dentin with a round bur~2. Enamel beveling~3. Enamel (30sec) etching with phosphoric acid~4. Application of AdheSE One and curing for 10sec~5. Composite-resin application using a transparent cervical matrix and curing for 40sec~6. Finishing and polishing
Study: NCT04396275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-1
Description: Cooked whole navy beans (300 kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-2
Description: Cooked whole yellow split peas (300 kcal)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food-3
Description: Cooked rice considered as control (300 kcal)
Study: NCT02156661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Study: NCT04401059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: First or third generation EGFR-TKIs
Description: refer to the drug label.
Study: NCT04516304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 tablets/d (2 in the morning and 2 in the evening)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 tablets/d (2 in the morning and 2 in the evening)
Study: NCT01748149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg twice a day (BID). Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.~Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery.
Study: NCT04516304

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: S-equol
Description: 4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: S-equol
Description: 4 tablets/d (2 in the morning and 2 in the evening), providing 10 mg S-equol total a day Other Names: •Equelle®
Study: NCT01495026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg, fasted state)
Description: Open-label, randomized, single dose, multi-stage, cross-over study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg, fasted state)
Description: Open-label, randomized, single dose, multi-stage, cross-over study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg, fed state)
Description: Commercial formulation of Dutasteride 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg, fed state)
Description: Commercial formulation of Dutasteride 0.5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC containing faster-release enteric-coated pellets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC containing faster-release enteric-coated pellets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC bioequivalent to Harnal-D tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)
Description: FDC bioequivalent to Harnal-D tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)
Description: FDC bioequivalent to Harnal-D tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)
Description: FDC bioequivalent to Harnal-D tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tablets with water (fasted state)
Description: Commercial formulation of Harnal-D Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tablets with water (fed state)
Description: Commercial formulation of Harnal-D Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D tablets without water (fasted state)
Description: Commercial formulation of Harnal-D Tablets
Study: NCT03142607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole gel
Description: 1% Metronidazole gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole gel
Description: 1% Metronidazole gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: 0.2% Chlorhexidene gluconate gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: 0.2% Chlorhexidene gluconate gel
Study: NCT01627704

Intervention type: DRUG
Group type: OTHER
Intervention: Fluoroestradiol (18F)
Description: 2-4 MBq/kg body mass, one single IV injection
Study: NCT03040024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalogram (EEG)
Description: A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electroencephalogram (EEG)
Description: A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
Study: NCT00794287

Intervention type: OTHER
Intervention: Taking blood samples
Description: No intervention is done. Only blood samples are taken.

Intervention type: OTHER
Intervention: Taking blood samples
Description: No intervention is done. Only blood samples are taken.
Study: NCT02318602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
Study: NCT03736044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF-blockers suspension in patients with rheumatoid arthritis
Description: in patients treated with anti-TNF the intervention consisted in anti-TNF drug withdrawal, after a preliminary careful examination of remission status; a 18 months (at least) follow up was performed.
Study: NCT02950506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
Study: NCT00796341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPELLE ENDOMETRIAL SAMPLING
Description: Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
Study: NCT01193712

Intervention type: PROCEDURE
Group type: OTHER
Intervention: temporary left ventricular endocardial pacing
Description: a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.